Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00551954|
Recruitment Status : Completed
First Posted : November 1, 2007
Last Update Posted : March 1, 2013
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes||Drug: acarbose Drug: placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Study Start Date :||July 2006|
|Actual Primary Completion Date :||July 2007|
20 weeks of treatment with acarbose (100 mg t.i.d.)
100 mg (tablets) t.i.d.
Placebo Comparator: 2
20 weeks of treatment with placebo (one tablet t.i.d.)
one tablet t.i.d.
- forearm blood flow assessed by forearm occlusion plethysmography after a mixed meal [ Time Frame: at baseline and after 20 weeks of treatment ]
- forearm blood flow assessed by forearm occlusion plethysmography in the fasting state, plasma glucose excursion in response to the mixed meal, insulin levels in response to the mixed meal, triglyceride levels in response to the mixed meal [ Time Frame: at baseline and after 20 weeks of treatment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00551954
|Principal Investigator:||Markolf Hanefeld, PhD||Center for Clinical Studies, Fiedlerstr. 34, 01307 Dresden, Germany|